0.5 indicates complete similarity [i.e., for a comparison between low and high BSA groups, overlap of 0.5 means there is 50% probability that a randomly selected patient with low BSA would have the same or greater PRO burden as one with high BSA]
Furthermore, there is zero data showing that BPC 157 fixes the underlying mechanisms of IBSsuch as visceral hypersensitivity (hypersensitive gut nerves), altered gut-brain signaling, or abnormal gut motility
Weight Loss and Body Composition Significant reductions in body weight: Phase 2 trial participants lost up to 1619% of body weight over 46 weeks, a result comparable to or greater than leading GLP-1 therapies
It has also been found to play a role in preventing the common cold, cancer, osteoarthritis, age-related macular degeneration, asthma, and more